Like many would-be acquisitions, Allergan isn't going down without a fight. Taking the position that Valeant's offer not only undervalues its business but it is too risky for shareholders given the "unsustainability of Valeant's business model." Ouch!
In this episode of "Market Checkup," Motley Fool health-care analysts David Williamson and Michael Douglass discuss Valeant's latest offer, why Allergan finds it offensive, and what is next for shareholders.
Also stay tuned for Michael's in-depth interview with Motley Fool Stock Advisor analyst Brendan Mathews on Valeant and why investors need to get excited about this unique pharma stock.
Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson and Michael Douglass have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.